PHARMD, Endowed Chair in Pharmaceutical Sciences, St. Jude
Biography
Dr. Relling has been a pioneer in both the science and clinical application of pharmacogenomics. Her research has resulted in seminal laboratory discoveries that unraveled the mechanisms of drug-induced adverse effects, and the integration of biologic, genomic, and pharmacologic discoveries into comprehensive clinical protocols, leading to improved cure rates for children with acute lymphoblastic leukemia. In recognition for her work she was elected to the Institute of Medicine (now National Academies of Medicine) in 2009 and received the Pediatric Oncology Award from ASCO. Mary has been recognized by the American Society for Clinical Pharmacology and Therapeutics. Mary, along with Dr. Teri Klein of Stanford, co-founded the Clinical Pharmacogenomics Implementation Consortium (CPIC) that has published pharmacogenetic guidelines for over sixty-five medications. These guidelines are now implemented around the globe. Mary received her Bachelor of Science degree from the University of Arizona and her PharmD from the University of Utah College of Pharmacy.
Session Abstract – PMWC 2023 Silicon Valley
Track 1 - January 27 9.00 A.M.-4.15 P.M.
Track Co-Chair:
Mary Relling, St. Jude
Pharmacists have long recognized that using unique patient characteristics to guide pharmacotherapy decision-making can improve drug response and mitigate drug-associated risks. Age, weight, and dietary habits were among the first patient-specific characteristics used to individualize pharmacotherapy. As technologies advanced, analytic tools that measure surrogate markers of liver and renal function, together with drug concentrations in biological fluids, were adopted to optimize therapeutic regimens. Cutting-edge genomic technologies are now being integrated into patient care for the selection of targeted therapies and identification of those at increased risk of poor pharmacotherapy outcomes. We’re excited to bring together experts who are advancing pharmacogenomics at scale through cutting edge clinical implementation, research, and education.
- PMWC 2023 PGx Award Ceremony:
Pioneer Honoree: Dan Roden, Vanderbilt University Medical Center
Luminary Honoree: Kelly E. Caudle, St. Jude
- Fireside Chat:
PMWC 2023 Pioneer Honoree Dan Roden, Vanderbilt University Medical Center with Mary Relling, St. Jude - Keynote by PMWC 2023 Luminary Honoree:
- Kelly E. Caudle, St. Jude - Fireside Chat:
Chair: Damon Hostin, Illumina
- Howard McLeod, Intermountain Health - Laboratory Testing and Reports
Chair: Kristy Crooks, University of Colorado
- Ann M. Moyer, Mayo Clinic
- Stuart Scott, Stanford University
- Implementation of PGx at UCSF
- Bani Tamraz, UCSF
- From Economics to Reimbursement (PANEL)
Chair: Sara Rogers, American Society of Pharmacovigilance
- Stirling Bryan, The University of British Columbia
- Ray Stultz, Optum
- Gabriel Bien-Willner, Palmetto GBA
- Policy Efforts to Address Barriers to PGx Adoption
Chair: Kristine Ashcraft, Invitae
- Pam Traxel, ACS CAN - PGx Practice Liability
Chair: Dan Hertz, University of Michigan
- Anthony Morreale, VA, San Diego
- Karen Merritt, Patient Advocate - Diversity, Equity, and Inclusion in Pharmacogenomics Implementation
- Carlos Bustamante, Galatea Bio
- Kathy Giacomini, UCSF - Implementation of PGx Program & PGx Clinic Services in a Large Rural Healthcare Setting
- April Schultz, Sanford
